Abstract:BackgroundVitamin D (VD) insufficiency or deficiency is a frequent comorbidity in Chinese women with postmenopausal osteoporosis (PMO). The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600).MethodsChinese PMO women (n = 219) were treated with 12-month ALN/D5600 (n = 111) or calcitriol (n = 108). Changes in 25(OH) D at month 12 were post hoc analyzed by the baseline 25 (OH) D status using the longitudinal analysis. The main safety outcome measures included serum calcium and phosphate and 24-h urine calcium, and the repeated measures mixed model was used to assess the frequencies of the calcium-phosphate metabolic disorders.ResultsAbsolute change in mean serum 25(OH) D level was the greatest in VD-deficient patients and least in VD-sufficient patients at months six and 12 (both, P < 0.01). Serum calcium level remained significantly lower in the ALN/D5600 treatment group than in the calcitriol treatment group throughout the 12 months. Mean 24-h urine calcium slightly increased in the ALN/D5600 treatment group and significantly increased in the calcitriol treatment group (+ 1.1 and + 0.9 mmol/L at months six and 12; both, P < 0.05). Calcitriol treatment was associated with more frequent hypercalciuria at month six (9.4% vs. 18.5%, P = 0.05), but not at month 12 (12.3% vs. 13.0%).ConclusionBaseline VD status predicted 25(OH) D improvement in PMO patients on 12-month ALN/D5600 treatment. The daily use of 0.25 μg of calcitriol was associated with more frequent hypercalciuria at month six, compared to ALN/5600 treatment, necessitating the safety re-evaluation of calcitriol at a higher dosage.

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects: 1. **Vitamin D insufficiency or deficiency**: Vitamin D (VD) insufficiency or deficiency is a common comorbidity among Chinese women with post - menopausal osteoporosis (PMO). Therefore, the study aims to explore the effects of alendronate combined with vitamin D3 (ALN/D5600) on the 25 - hydroxyvitamin D [25(OH)D] levels and calcium - phosphorus metabolism in these patients. 2. **Evaluation of treatment effects**: By comparing the effects of alendronate combined with vitamin D3 (ALN/D5600) and calcitriol treatment, evaluate which treatment method is more conducive to improving 25(OH)D levels and whether it can effectively relieve the symptoms of PMO patients. 3. **Re - evaluation of safety**: Re - evaluate the safety of these two treatment regimens for calcium - phosphorus metabolism, especially focusing on the safety issues of long - term use of higher - dose calcitriol. ### Specific problem description - **Background problem**: Vitamin D insufficiency or deficiency is very common among post - menopausal osteoporosis patients, especially among Chinese women. This condition requires specific medical interventions to maintain sufficient 25(OH)D levels. - **Treatment option selection**: The study compared two treatment regimens: - Oral administration of 70 mg alendronate and 5600 IU vitamin D3 once a week (ALN/D5600) - Oral administration of 0.25 micrograms of calcitriol daily - **Efficacy and safety**: The study not only focuses on the treatment effect, but also pays special attention to safety issues such as calcium - phosphorus metabolism disorders that may occur during the treatment process. ### Research objectives - **Evaluation of the improvement of 25(OH)D levels**: Determine whether the ALN/D5600 combination can significantly improve the 25(OH)D levels of patients, and analyze the relationship between the baseline 25(OH)D status and the increase in serum 25(OH)D during the treatment period. - **Safety of calcium - phosphorus metabolism**: Re - evaluate the effects of the two treatment regimens on calcium - phosphorus metabolism, especially problems such as hypercalciuria that may be caused by calcitriol treatment. ### Conclusion The study shows that alendronate combined with vitamin D3 treatment (ALN/D5600) can significantly improve the 25(OH)D levels of Chinese post - menopausal osteoporosis patients and shows good safety in terms of calcium - phosphorus metabolism. In contrast, although calcitriol treatment can also improve 25(OH)D levels, it may lead to higher blood calcium levels and 24 - hour urinary calcium excretion, and its long - term use safety needs further evaluation.

Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal

Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment

Safety and effects of calcifediol 0.266 milligrams soft capsules monthly and cholecalciferol 25000 international units monthly in osteoporotic women undergoing therapy with alendronate: a cross-sectional study

The Efficacy and Safety of Calcitriol And/or Caltrate D in Elderly Chinese Women with Low Bone Mass

Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

Abdominal injuries.

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis

Effect of 2 Years of Monthly Calcifediol Administration in Postmenopausal Women with Vitamin D Insufficiency

Economic evaluations and diabetes.

Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation

Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

Efficacy of the combination of Tenghuangjiangu tablets, alfacalcidol capsules and caltrate D3 tablets in osteoporotic vertebral compression fracture, and their effects on bone metabolic indices

Alendronate Versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials.

A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density

Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial

A pain in the neck--imaging in neck sepsis.

Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

Monte Carlo study of out-of-field exposure in carbon-ion radiotherapy with a passive beam: Organ doses in prostate cancer treatment.